Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease

dc.creator	Gkiouras K., Grammatikopoulou M.G., Simopoulou T., Daniil Z., Bogdanos D.P.	en
dc.date.accessioned	2023-01-31T07:42:53Z
dc.date.available	2023-01-31T07:42:53Z
dc.date.issued	2021
dc.identifier	10.1007/s10067-021-05845-x
dc.identifier.issn	07703198
dc.identifier.uri	http://hdl.handle.net/11615/72478
dc.description.abstract	[No abstract available]	en
dc.language.iso	en	en
dc.source	Clinical Rheumatology	en
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109258249&doi=10.1007%2fs10067-021-05845-x&partnerID=40&md5=0a657b5919429c9610019a9f315dc1d4
dc.subject	cyclophosphamide	en
dc.subject	mycophenolate mofetil	en
dc.subject	cyclophosphamide	en
dc.subject	mycophenolic acid	en
dc.subject	adverse event	en
dc.subject	comparative effectiveness	en
dc.subject	controlled study	en
dc.subject	diffusing capacity for carbon monoxide	en
dc.subject	drug efficacy	en
dc.subject	forced vital capacity	en
dc.subject	human	en
dc.subject	interstitial lung disease	en
dc.subject	Letter	en
dc.subject	meta analysis (topic)	en
dc.subject	patient safety	en
dc.subject	systematic review (topic)	en
dc.subject	systemic sclerosis	en
dc.subject	complication	en
dc.subject	Cyclophosphamide	en
dc.subject	Humans	en
dc.subject	Lung Diseases, Interstitial	en
dc.subject	Mycophenolic Acid	en
dc.subject	Scleroderma, Systemic	en
dc.subject	Springer Science and Business Media Deutschland GmbH	en
dc.title	Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease	en
dc.type	other	en

Fichier(s) constituant ce document

Fichiers	Taille	Format	Vue
Il n'y a pas de fichiers associés à ce document.